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The enzymes LSD1 and Set1A 
cooperate with the viral protein 
HBx to establish an active hepatitis 
B viral chromatin state
Valentina Alarcon1, Sergio Hernández2, Lorena Rubio1, Francisca Alvarez1, Yvo Flores1, 
Manuel Varas-Godoy3, Giancarlo V. De Ferrari4, Michael Kann5,6,7, Rodrigo A. Villanueva2 & 
Alejandra Loyola1,8
With about 350 million people chronically infected around the world hepatitis B is a major health 
problem. Template for progeny HBV synthesis is the viral genome, organized as a minichromosome 
(cccDNA) inside the hepatocyte nucleus. How viral cccDNA gene expression is regulated by its 
chromatin structure; more importantly, how the modulation of this structure impacts on viral 
gene expression remains elusive. Here, we found that the enzyme SetDB1 contributes to setting 
up a repressed cccDNA chromatin state. This repressive state is activated by the histone lysine 
demethylase-1 (LSD1). Consistently, inhibiting or reducing LSD1 levels led to repression of viral gene 
expression. This correlates with the transcriptionally repressive mark H3K9 methylation and reduction 
on the activating marks H3 acetylation and H3K4 methylation on viral promoters. Investigating the 
importance of viral proteins we found that LSD1 recruitment to viral promoters was dependent on 
the viral transactivator protein HBx. Moreover, the histone methyltransferase Set1A and HBx are 
simultaneously bound to the core promoter, and Set1A expression correlates with cccDNA H3K4 
methylation. Our results shed light on the mechanisms of HBV regulation mediated by the cccDNA 
chromatin structure, offering new therapeutic targets to develop drugs for the treatment of chronically 
infected HBV patients.
Hepatitis B virus (HBV) infection remains a major health problem worldwide, in spite of the existence of an 
effective vaccine since the eighties. The World Health Organization estimates that more than 350 million people 
worldwide suffer from chronic hepatitis caused by HBV infection1,2. In these patients, the virus replicates persis-
tently, which can result in cirrhosis and hepatocellular carcinoma (HCC). Although there is a correlation between 
HBV infection and the development of HCC, the molecular mechanisms involved remain elusive3.
HBV is an enveloped pararetrovirus containing a partially double stranded DNA genome (relaxed circular 
DNA, rcDNA), which is surrounded by the viral capsid. The infective cycle starts with the binding of HBV to its 
cellular receptor, the sodium taurocholate cotransporting polypeptide (NTCP) protein, localized in the hepato-
cyte4. The virus is incorporated into the cell using endocytosis followed by release of the capsid and its transport 
to the nucleus. After passing the nuclear pores the capsid dissociates leading to genome release. The genome is 
repaired to a covalently closed circular double-strand DNA (cccDNA) of 3.2 kb. This cccDNA is the replicative 
intermediate serving as a template for the transcription of all the viral transcripts, including the pregenomic 
RNA5. The cccDNA molecule, responsible for persistent infection, is kept in the nucleus of the infected hepat-
ocyte as an episomal DNA6. It is organized as a minichromosome by its association with cellular histones and 
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non-histone proteins7,8. Recent reports revealed that the cccDNA chromatin structure regulates the HBV replica-
tion and transcription9–15, utilizing host mechanisms that control cellular genome expression16,17. Indeed, acetyl-
ation of histones H3 and H4 bound to the cccDNA plays a critical role in HBV expression. There is a temporal 
correlation between acetylation and the level of HBV replicative intermediates9. Moreover, in chronically infected 
patients, the acetylation status of histones H3 and H4 correlates with viremia levels9. Furthermore, IFN-α , clin-
ically used as an inhibitor of cccDNA transcription and HBV replication, leads to hypoacetylation of histones 
bound to the HBV cccDNA10,11.
The viral protein HBx plays a pivotal role in HBV viral transcription. On one hand it regulates the degradation 
of the structural maintenance of chromosomes (SMC) complex Smc5/6 avoiding its binding and repression of 
viral cccDNA18. On the other hand it modulates the cccDNA chromatin state by regulating the recruitment of 
chromatin modifying enzymes11,14,19,20. In its absence, the viral genome exists in a repressed chromatin state. The 
histone deacetylases HDAC1 and hSirt1, but not histone acetyltransferase p300, are bound to viral promoters 
on HBV X(-) mutant virus11, a virus that is impaired in viral replication21. Consistently, cccDNA bound histones 
H3 and H4 are hypoacetylated in the HBV X(-) mutant11. In addition to histone hypoacetylation, the silencing 
mechanism involves methylation of histone H3 on lysine 9 (H3K9me), a hallmark of heterochromatin, by the 
methyltransferase SetDB1; and the recruitment of the heterochromatin protein HP120. In the presence of viral 
protein HBx the cccDNA forms an active chromatin state, with reduced levels of H3K9me20. However, the mecha-
nisms involved in this chromatin state switching process remain elusive. Thus, we focused on histone demethylase 
lysine-specific demethylase-1 (LSD1). LSD1 protein can mediate either transcriptional repression or activation by 
demethylating H3K4me1/2 or H3K9me1/2, respectively22. Indeed, reactivation of the herpes virus from latency 
involves the recruitment of LSD1, which demethylates the repressive mark H3K9me2 present on the repressed 
immediate early herpes viral promoter genes, allowing transcriptional activation23,24. In this report, we utilized 
an in vitro HBV replication model system that uses a HBV genotype F clone15,25 to investigate whether LSD1 
activates HBV transcription. Interestingly, we found that viral protein HBx recruits LSD1 to HBV viral promoters 
correlating with a reduction of the methylation on H3K9. In addition, HBx recruits the enzyme Set1A to viral 
promoters to trimethylate H3K4, a mark associated with transcriptional activation, thus helping to establish an 
active viral chromatin state.
Results
SetDB1 represses HBV transcription. We investigated the chromatin state of the HBV genome in an in 
vitro HBV replication model system based on the transfection of linear HBV genome monomeric molecules con-
taining cohesive ends that allows its circularization15. We performed a Chromatin Immunoprecipitation (ChIP) 
assay of two covalent post-translational modifications, H3K9me3 and H3ac, associated with transcriptional 
repression and activation, respectively. We then performed quantitative PCR to examine the presence of these 
marks on histones bound to three HBV promoters: the proximal promoter region of the core viral gene, which 
drives transcription of the pre-genomic RNA; the HBx promoter, which gives rise to the viral regulatory protein 
HBx, and the preS1 promoter, which drives transcription of the LHBsAg5. We found that the H3K9me3 mark was 
enriched on the three viral promoters, whereas H3ac was low or undetected (Fig. 1A). This result suggests that the 
HBV genome is organized in a repressed chromatin state. We then investigated whether the enzyme SetDB1 was 
involved in repressing HBV transcription, as recently shown20. Thus, we specifically reduced the levels of SetDB1 
protein by using shRNA to knock down SetDB1 mRNAs (shSetDB1). We performed the experiment by treating 
the cells with and without shSetDB1 48 h prior to transfecting the HBV genome. Western blot analysis confirmed 
a reduction in SetDB1 protein levels after the treatment (Fig. 1B). We then examined the effect of shSetDB1 on 
HBV transcription by qPCR using specific primers. For this, we analyzed cytoplasmic viral core particles and 
found that, upon shSetDB1 treatment, viral particles DNA increased significantly (Fig. 1C). Therefore, the data 
indicate that SetDB1 negatively regulates the transcription of viral promoters.
LSD1 increases the levels of HBV replicative intermediates. We then explored the molecular mech-
anisms by which repressed viral promoters become active. Given that the herpes virus regulates its reactivation 
from latency in part by recruiting LSD1 to demethylate H3K9me2 on repressed immediate early herpes viral pro-
moter genes23,24, and that histone H3 bound to the HBV cccDNA is methylated at residue K9 (Fig. 1A), we inves-
tigated the effect of LSD1 on HBV replication. For this, we co-transfected Huh7 cells with the plasmid-free HBV 
genome plus either a plasmid encoding Flag-tagged LSD1 or the empty vector as a negative control, as illustrated 
in Fig. 2A. Western blot analysis confirmed that after 24 h LSD1 was overexpressed in the cells (Fig. 2B). We then 
isolated the HBV replicative intermediates cccDNA and cytoplasmic viral core particles from transfected cells and 
quantified the viral DNA intermediates. We observed that the levels of both viral intermediates increased signif-
icantly upon overexpressing LSD1 (Fig. 2C). Thus, LSD1 increases the levels of HBV replicative intermediates.
Inhibition of LSD1 represses HBV transcription and replication. To investigate further whether 
LSD1 regulates the transcription and replication of HBV, we utilized an LSD1 inhibitor. LSD1 demethylates lysine 
residues via a Flavin-adenine dinucleotide-dependent reaction that is inhibited by monoamino oxidase inhibitors 
(MAOI) such as pargyline23. Thus, Huh7 cells were transfected with the HBV genome in the presence or absence 
of 0.5 mM pargyline, as illustrated in Fig. 3A. Pargyline did not affect cell viability, as determined by trypan blue 
staining (Supplementary Figure 1A). We decided to analyze by ChIP covalent post-translational modifications 
of the histones located on the proximal promoter region of the core viral gene, because it plays an important role 
in the regulation of HBV replication. Interestingly, after 24 h treatment, the histone modifications on the core 
promoter switched. Histone H3 became hypoacetylated and displayed lower levels of H3K4me3 compared to 
untreated cells. In contrast, the levels of H3K9me3 increased (Fig. 3B). Thus, ChIP analyses indicate that par-
gyline changed the state of the core viral gene promoter, switching from an activated to a repressed state. We then 
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examined the effect of pargyline on the viral protein expression. We performed immunofluorescence assays and 
observed reduction of capsids upon pargyline treatment, consistent with the ChIP results (Fig. 3C). Furthermore, 
the examination of the HBs and HBe viral antigens, used as markers of acute infection and active replication, 
respectively, showed that pargyline gave rise to a reduction of both viral antigens levels (Fig. 3D). We finally 
investigated the effect of pargyline on HBV replicative intermediates and found that cccDNA and cytoplasmic 
viral core particles significantly decreased (Fig. 3E). Taken together, the data suggest that LSD1 regulates the HBV 
cycle, through a mechanism that involves the demethylation of H3K9, switching the cccDNA chromatin state 
from a repressed to an activated state.
Figure 1. SetDB1 represses HBV transcription. (A) Covalent post-translational modifications on histone H3 
were determined by Chromatin Immunoprecipitation (ChIP) analysis using specific antibodies, as indicated. 
Immunoprecipitated DNA was quantified by qPCR using specific primers as detailed in Material and Methods. 
The results are expressed as enrichment fold change with respect to H3. The standard deviation was obtained 
from three independent experiments. (B) SetDB1 knock down was examined by Western blot using specific 
antibodies. Beta actin was used as a loading control. (C) HBV cytoplasmic intermediate levels were determined 
by qPCR using specific primers. The result is shown as fold changes with respect to the control. The standard 
deviation was obtained from three independent experiments. *p < 0.05, Student´s t-test.
Figure 2. LSD1 increases the levels of HBV replicative intermediates. (A) The scheme depicts the 
experimental procedure to overexpress LSD1. Human hepatocarcinoma Huh7 cells were transfected with the 
HBV genome together with either a plasmid encoding a Flag-tagged LSD1 or a Flag protein as a control. (B) 
Western blot analysis to monitor LSD1 overexpression. Beta actin was used as a loading control. (C) HBV 
cccDNA and cytoplasmic intermediate levels were determined by qPCR using specific primers. The results are 
shown as fold changes with respect to the control. The standard deviation was obtained from three independent 
experiments. *p < 0.05, Student´s t-test.
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Knock down of LSD1 represses HBV transcription and replication. To demonstrate that the effects 
observed with pargyline were due to LSD1 inhibition, we specifically reduced the levels of LSD1 protein by using 
siRNA (siLSD1). We performed the experiment as illustrated in Fig. 4A, by treating the cells with and without 
siLSD1 24 h prior to transfecting the HBV genome. Western blot analysis confirmed the LSD1 reduction after the 
treatment (Fig. 4B). ChIP assay showed that histone H3 levels were enriched in two viral promoters upon LSD1 
reduction (Fig. 4C). We then examined histone post-translational modifications. Because the levels of histone H3 
varied between untreated and siLSD1 treated cells, we normalized the H3 modification ChIP results against the 
H3 value for each sample, as explained in Material and Methods. We observed that H3K9 di- and trimethylation 
(H3K9me2 and H3K9me3) were significantly enriched on the three promoters (Fig. 4D,E). Consistent with the 
enrichment of repressive marks, H3ac and H3K4me3 modifications that correlate with transcriptional activation 
were decreased (Fig. 4F,G). We then examined whether the changes in histone modifications on viral promoters 
mediated by siLSD1 impacted on HBV transcription and replication. For this, we analyzed HBV replicative inter-
mediates cccDNA and cytoplasmic viral core particles and found that both intermediates decreased significantly 
(Fig. 4H). Taken together, the data indicate that LSD1 positively regulates transcription of viral promoters by 
activating the cccDNA chromatin state.
LSD1 is recruited to HBV promoters in an HBx-dependent manner. To investigate how LSD1 acti-
vates viral transcription, we first explored whether LSD1 binds to viral promoters. We overexpressed Flag-tagged 
LSD1 and performed Flag-ChIP analysis. We found a specific binding of LSD1 on the three viral promoters 
Figure 3. Inhibition of LSD1 represses HBV transcription and replication. (A) The scheme depicts the 
experimental procedure. Human hepatocarcinoma Huh7 cells were grown in the presence or absence of 
0.5 mM of the LSD1 inhibitor pargyline. 16 h after, cells were transfected with the HBV genome in the presence 
or absence of pargyline. (B) Covalent post-translational modifications on histone H3 were determined by 
Chromatin Immunoprecipitation (ChIP) analysis using specific antibodies as indicated. Immunoprecipitated 
DNA was quantified by qPCR using specific primers to the core promoter as detailed in Material and Methods. 
Histone modifications were normalized against the immunoprecipitated H3. The standard deviation was 
obtained from three PCR reactions and the graph is representative of three independent experiments. (C) 
Immunofluorescence analyses of pargyline treated and untreated cells were performed using specific antibodies 
against the core protein and DAPI staining. On the right, the graph shows pixel intensity in arbitrary units. The 
staining intensity was quantified on at least 100 cells using Image J software. Standard deviation was obtained 
from three independent experiments. (D) The quantity of viral antigens in the supernatant of the transfected 
cells was determined by ELISA, using specific antibodies against the HBs and HBe proteins. The results are 
shown as fold changes with respect to the control. The standard deviation was obtained from three independent 
experiments. (E) HBV cccDNA and cytoplasmic intermediate levels were determined by qPCR using specific 
primers. The results are shown as fold changes with respect to the control. The standard deviation was obtained 
from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, Student´s t-test.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:25901 | DOI: 10.1038/srep25901
studied (Fig. 5A and Supplementary Figure 1B). LSD1 cannot directly interact with DNA and it is recruited to 
promoter regions by interacting with transcriptional regulators26. Given that the viral HBx protein regulates the 
binding of several chromatin modifying enzymes to the cccDNA11,14,19, we investigated whether HBx and LSD1 
bind to the promoters at the same time by reChIP. We co-transfected the HBV genome with a vector expressing 
either a tagged version of HBx (Flag-HBx) or an empty vector. We then performed Flag-ChIP assays and found 
Flag-HBx on the three viral promoters (Fig. 5B, left). We then immunoprecipitated the Flag-HBx ChIP samples 
with an antibody against LSD1 (Fig. 5B, right) and found LSD1 present in promoters containing HBx protein. We 
conclude that HBx and LSD1 bind to viral promoters at the same time. To confirm the role of HBx, we took advan-
tage of a mutant HBV genome carrying a stop codon in amino acid 8 of the HBx open reading frame (HBV X-)11  
and introduced the mutation on the HBV genotype F genome. We performed ChIP assays in the absence of 
Figure 4. Knock down of LSD1 represses HBV transcription and replication. (A) The scheme depicts the 
experimental procedure. Human hepatocarcinoma Huh7 cells were transfected with 10 nM of either control or 
LSD1 siRNA. 24 h after, cells were transfected with the HBV genome. (B) LSD1 knock down was determined 
by Western blot using specific antibodies. Beta actin was used as a loading control. (C–G) Covalent post-
translational modifications on histone H3 were determined by ChIP analysis using the specific antibodies as 
indicated. Immunoprecipitated DNA was quantified by qPCR using specific primers as detailed in Material 
and Methods. When analyzing histone modifications, we normalized the data against the immunoprecipitated 
H3. The standard deviation was obtained from three PCR reactions and the graphs are representative of three 
independent experiments. (H) HBV cccDNA and cytoplasmic intermediate levels were determined by qPCR 
using specific primers. The results are shown as fold changes with respect to the control. The standard deviation 
was obtained from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, Student´s t-test.
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HBx. Consistent with a previous report20, viral promoters were enriched on histone H3 as well as on the marks 
H3K9me2 and H3K9me3, in the absence of HBx (Fig. 5C). In contrast, the viral promoters showed reduced levels 
of H3K4me3 in the absence of HBx (Fig. 5C). As expected, the HBV X- cccDNA chromatin state correlated with 
a repressed HBV gene expression, as illustrated with HBs viral antigen levels (Fig. 5D and ref. 15). Thus, these 
results suggest that in the absence of HBx protein LSD1 is not recruited to cccDNA, leading to enrichment in 
H3K9 methylation and the establishment of a repressed HBV cccDNA chromatin state.
Set1A participates in the establishment of the mark H3K4me3 on HBV promoters. Given that 
the active cccDNA chromatin state correlates with enrichment of the mark H3K4me3, whereas the repressed state 
with low levels of H3K4me3, we investigated how this modification is imposed on the HBV cccDNA. Thus, we 
first examined whether the H3K4 methyltransferase Set1A, the catalytic subunit of the H3K4 methyltransferase 
complex COMPASS27, binds to viral promoters. We performed ChIP analysis with antibodies against Set1A and 
found it specifically bound to the three viral promoters studied (Fig. 6A). We then investigated whether HBx 
and Set1A bind to the promoters at the same time by reChIP. We co-transfected the HBV genome and a vector 
expressing a tagged version of HBx (Flag-HBx). We then performed Flag-ChIP assays to isolate Flag-HBx bound 
cccDNA DNA (Fig. 6B, left), followed by Set1A-ChIP (Fig. 6B, right) and found Set1A present at core promot-
ers containing HBx protein. We conclude that HBx and Set1A bind to viral promoters at the same time. We 
then investigated the effect of modulating Set1A cellular levels on cccDNA H3K4 methylation by overexpressing 
(Fig. 6C, left) or reducing (Fig. 6D, left) Set1A protein. ChIP assays showed that H3K4me3 was enriched on the 
Figure 5. LSD1 is recruited to HBV promoters in an HBx-dependent manner. (A) Human hepatocarcinoma 
HepG2 cells were transfected with the wild type HBV genome together with either a plasmid encoding for 
a Flag-tagged LSD1 or a Flag protein as a control. Flag-LSD1 recruitment to viral promoters was assayed 
by ChIP analysis. Immunoprecipitated DNA was quantified by qPCR using specific primers as detailed in 
Material and Methods. The results are expressed as % of input. The standard deviation was obtained from three 
independent experiments. (B) Human hepatocarcinoma HepG2 cells were transfected with the wild type HBV 
genome together with either a plasmid encoding for a Flag-tagged HBx or a Flag protein as a control. Flag-HBx 
recruitment to viral promoters was assayed by ChIP analysis (left). Then the Flag-HBx immunoprecipitated 
samples were reChIP with antibodies against LSD1 or IgG antibodies as control (right). Immunoprecipitated 
DNA was quantified by qPCR using specific primers as detailed in Material and Methods. The results are 
expressed as % of input. (C) Covalent post-translational modifications on histone H3 were determined by ChIP 
analysis using the specific antibodies, as indicated. Immunoprecipitated DNA was quantified by qPCR using 
specific primers as detailed in Material and Methods. When analyzing histone modifications, we normalized 
the data against the immunoprecipitated H3. The standard deviation was obtained from three PCR reactions 
and the graphs are representative of three independent experiments. (D) The quantity of viral antigens in the 
supernatant of WT and HBV- transfected cells after 72 h was determined by ELISA, using specific antibodies 
against the HBs protein. In each case, the results are presented as a signal-to-cutoff (S/CO) ratio. The standard 
deviation was obtained from four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, Student´s t-test.
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three viral promoters upon Set1A overexpression (Fig. 6C, right). In contrast, knocking down Set1A resulted in the 
reduction of the mark H3K4me3 on viral promoters (Fig. 6D, right). Taken together, the results show that Set1A 
establishes the mark H3K4me3 on HBV promoters and that this mark can be altered by modulating Set1A levels.
Discussion
In chronically infected patients the HBV genome remains in the nucleus of the hepatocyte as a minichromosome, 
structured similarly to the cellular chromatin. Despite the knowledge that has been gained about the impact of 
chromatin structure on gene expression, only a few reports have investigated how histone modification changes 
on the cccDNA minichromosome influence HBV gene expression11,14,15,19,20. In this study, we have shown that the 
enzyme SetDB1 contributes to establishing a repressed HBV cccDNA chromatin state, consistent with a recent 
report20. This repressed cccDNA chromatin state is activated by the enzymes LSD1 and Set1A. Our results suggest 
Figure 6. Set1A participates in the establishment of the mark H3K4me3 on HBV promoters. (A) Human 
hepatocarcinoma Huh7 cells were transfected with the wild type HBV genome. Set1A recruitment to viral 
promoters was assayed by ChIP analysis. Immunoprecipitated DNA was quantified by qPCR using specific 
primers as detailed in Material and Methods. The results are expressed as % of input. The standard deviation 
was obtained from two PCR reactions and the graph is representative of three independent experiments. 
(B) Human hepatocarcinoma HepG2 cells were transfected with the wild type HBV genome together with a 
plasmid encoding for Flag-tagged HBx. Flag-HBx recruitment to viral promoters was assayed by ChIP analysis 
(left). Then the Flag-HBx immunoprecipitated samples were reChIP with antibodies against Set1A or IgG 
antibodies as control (right). Immunoprecipitated DNA was quantified by qPCR using specific primers for core 
promoter. The results are expressed as % of input. (C,D, left) Western blot analyses to monitor overexpression 
(C) and knock down (D) of Set1A. Β eta actin was used as a loading control. (C,D) H3K4me3 modification was 
determined by ChIP analysis using specific antibodies from cells overexpressing (C) or knocking down (D) 
Set1A. Immunoprecipitated DNA was quantified by qPCR using specific primers as detailed in Material and 
Methods. We normalized the data against the immunoprecipitated H3. The standard deviation was obtained 
from two PCR reactions and the graphs are representative of three independent experiments.
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that LSD1 mediates its activation by demethylating H3K9, whereas Set1A by methylating H3K4. In addition, we 
showed that both LSD1 and Set1A are recruited to viral promoters in an HBx dependent manner.
We found that 24 h after HBV genome transfection, histones H3 bound to HBV promoters are hypoacetylated 
and methylated at residue K9, both marks associated with transcriptional repression (Fig. 1). It has been suggested 
that the establishment of these marks is part of a cellular mechanism aimed at silencing the virus20. Therefore, 
in order for active HBV transcription and replication to occur, the repressed modifications need to be removed 
and active marks imposed on the HBV minichromosome. The viral HBx protein plays a key role in this activating 
mechanism by recruiting chromatin modifying enzymes, such as the histone acetyltransferase p30011,14,19,20. In its 
absence, histone deacetylases are recruited to the cccDNA instead11. Our results indicate that HBx is necessary 
for the recruitment of the enzymes LSD1 and Set1A to participate in the activation of the repressed HBV cccDNA 
chromatin state. Intriguingly, LSD1 can demethylate histone H3 on lysines 4 and 9, depending on the proteins 
that it interacts with. When LSD1 associates with the Co-REST complex it contributes to the establishment of 
transcriptional repression by removing H3K4 methylation. In contrast, when LSD1 associates with the androgen 
receptor, it establishes a transcriptionally active state by removing H3K9 methylation28. We showed that LSD1 is 
required for a reduction of the methylation levels of H3K9, but not H3K4, bound to the HBV cccDNA minichro-
mosome; however, how LSD1 activity is regulated in the HBV context remains unknown. Further experiments 
should investigate whether androgen receptor and the HBx protein work together to regulate the association 
of LSD1 to viral promoters and its activity. Our results support the model proposed by the Levrero’s group11, in 
which the viral HBx protein regulates the cccDNA chromatin state by recruiting chromatin modifiers to viral 
promoters (Fig. 7), including the histone acetyltransferase p300, the histone demethylase LSD1, and the histone 
methyltransferase Set1A, as suggested in here. As a consequence, an active HBV cccDNA chromatin state is estab-
lished that promotes HBV expression and production of viral progeny.
For the treatment of chronically infected patients there are currently two types of antivirals: interferon-α , 
which stimulates the immune system and can eventually clear HBV29, and nucleotide/nucleoside analogs, which 
interfere with the viral replication by inhibiting the viral polymerase/reverse-transcriptase activity. However, only 
20–30% of the treated patients eradicate the infection, due to the persistence of the cccDNA in infected hepato-
cytes30. In addition, HBV has developed resistance to these type of drugs31. Therefore, it is necessary to develop 
new therapeutic targets and compounds. We and others have shown that the cccDNA minichromosome structure 
is dynamic and viral gene expression adapts its outcome according to changes on the chromatin including his-
tone modifications. For instance, upon treatment with deacetylase inhibitors, the histones bound to the cccDNA 
become hyperacetylated, correlating with activation of viral gene expression9,15. Our results indicate that modu-
lating the cccDNA chromatin structure towards a repressed chromatin state is a potential therapeutic approach 
for chronically infected HBV patients. We have shown that by inhibiting LSD1 demethylase with pargyline, an 
irreversible non-selective monoamine oxidase inhibitor, viral gene expression is repressed. Interestingly, par-
gyline is used in the clinic by patients suffering from hypertension; thus, it would be interestingly to explore its 
effect in an in vivo HBV animal model as a potential drug for chronically infected HBV patients. However, the 
use of pargyline in HBV chronically infected patients has the limitation that it is not a specific LSD1 inhibitor. 
Giving that LSD1 is overexpressed in many types of cancers and it is believed that its overexpression contributes 
to carcinogenesis, screening for LSD1 inhibitors has been intently pursued, thus specific LSD1 inhibitors have 
been developed32.
However, it should be pointed out that therapies based on the inhibition of cellular enzymes, such as LSD1, 
will most likely have side effects. Therefore, ways of blocking the recruitment of chromatin modifying enzymes, 
such as LSD1, specifically to the cccDNA minichromosome rather than inhibiting the enzyme would be a safer 
approach for patient treatment. Given the evidence that the viral protein HBx is required for the recruitment of 
many chromatin modifying enzymes to the cccDNA11,14,19, HBx protein would be a target to explore. Thus, our 
results highlight the importance of understanding how the cccDNA minichromosome is structured and how this 
structure as well as changes in it can control HBV gene expression and replication.
Materials and Methods
Antibodies, drugs, and primers. Antibodies: β -actin (Millipore #04-1116), FLAG (Sigma Aldrich 
#F3165-2MG), hepatitis B virus core antigen (Dako # B0586), histone H3 (Abcam #ab1791), H3ac (Merck 
#06-599), H3K4me3 (Abcam #ab8580), H3K9me2 (Abcam #ab1220), H3K9me3 (Abcam #ab8898), LSD1 
Figure 7. HBx contributes to establish an active cccDNA chromatin state. The viral HBx protein plays a 
key role in the establishment of an active cccDNA chromatin state by regulating the recruitment of chromatin 
modifying enzymes, including LSD1 and Set1A, as demonstrated here.
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(Abcam #ab17721), anti-FLAG beads (Sigma Aldrich #A2220), Set1A (Bethyl #A300-290A), SetDB1 (Abcam 
#ab12317). Drugs: Pargyline hydrochloride (sc-215676A, Santa Cruz Biotechnology). Primer cccDNA: Forward 
5′ -ACTCTTGGACTTTCAGGAAGG-3, Reverse 5′ -TCTTTATAAGGGTCAATGTCCAT-3′ . Primer core pro-
moter region: Forward 5′ -GGAAGGTCAATGACCTGGATC-3′ , Reverse 5′ - ATGCCTACAGCCTCCTAATAC-3′ ; 
Primer PreS1 promoter region: Forward 5′ -CCCTATTATCCTGATAACGTGG-3′ ; Reverse 5′ -GC 
TACGTGTGGATTCTCTCTT-3′ . Primer X promoter region: Forward 5′ -ATTGGCCATCAGCGCATGCG-3′ ; 
Reverse 5′ -AGCTGCAAGGAGTTCCGCAGT-3′ . Primer GAPDH promoter region: Forward 5′ -GATGCC 
CCCATGTTTGTGAT-3′ , Reverse 5′ -GGTCATGAGCCCTTCCACAAT-3′ .
HBV DNA transient transfection. Full length HBV genotype F genome25 was released by SapI 
(Fermentas) digestion from pCR-XL-TOPO containing the HBV DNA. After digestion, the 3.2 kb DNA was puri-
fied with the Wizard SV Gel and PCR Clean-Up System (Promega) according to the manufacturer’s instructions. 
Huh-7 and HepG2 human hepatocarcinoma cells were seeded at a density of 6 × 105 cells in 60 mm dishes and 
transfected after 24 h with 1.3 μ g of digested HBV DNA using Lipofectamine 2000 (Life Technologies). Cells were 
harvested 24 h after transfection. For drug treatment, 0.5 mM pargyline hydrochloride was added to cells 16 h 
before and during HBV transfection. For shRNA treatment, 1.3 μ g of pLL3.7 plasmid either with luciferase as con-
trol or SetDB1 target sequence (GCTCAGATGATAACTTCTGTA)33 was transfected with Lipofectamine 2000 
48 h before HBV transfection. For siRNA treatment, 10 nM of either control siRNA (Silencer negative control 
#1 siRNA, Ambion, Life Technologies), human LSD1 siRNA (sc-60970, Santa Cruz Biotechnology), or human 
Set1A siRNA (sc-76484, Santa Cruz) was transfected with Lipofectamine.
For LSD1 and Set1A overexpression, cells were co-transfected with HBV DNA and either empty-, 
LSD1-FLAG, or FLAG-Set1A containing vector. The full-length HBV genotype F genome deficient in the expres-
sion of HBx was previously described34.
Purification and analysis of HBV cytoplasmic intermediates and cccDNA. HBV intermediates 
were purified according to35. In brief, transfected cells were lysed with lysis buffer (10 mM Tris-Cl, pH 7.5; 50 mM 
NaCl; 1 mM EDTA; 0.5% Nonidet P40) in the presence of proteinase inhibitors for 4 min on ice. Nuclei were 
sedimented by centrifugation at 2,400 × g for 10 min. The supernatant was treated with 300 U DNase I (Winkler) 
for 1 h at 37 °C. Proteins were digested with 0.4 U of proteinase K (New England Biolabs) at 37 °C overnight and 
nucleic acids were purified by phenol–chloroform (1:1) extraction and ethanol precipitation. The nuclei were 
disintegrated vortexing them for 30 sec in nuclei lysis buffer (100 mM NaOH; 6% SDS), followed by incubation 
for 30 min at 37 °C. Sodium acetate was added to a final concentration of 600 mM and the pellet was discarded 
after centrifugation at 9,600 × g for 20 min. The cccDNA was purified twice by phenol-chloroform (1:1) extrac-
tion and then precipitated with ethanol. HBV intermediates were analyzed by real-time PCR (KAPA SYBR FAST, 
Universal qPCR kit).
ELISA. Post-transfection supernatants were taken, and samples analyzed by ARCHITECT i1000 (Abbott) to 
detect either HBsAg or HBeAg, to obtain a signal-to-cutoff ratio, and then expressed as a % of untreated cells.
cccDNA chromatin immunoprecipitation assays. Chromatin immunoprecipitation was performed 
according to36 with modifications. In brief, transfected cells were crosslinked for 10 min with 1% formaldehyde 
at room temperature. The reaction was quenched with glycine at a final concentration of 125 mM. For the anal-
ysis of LSD1 and Set1A recruitment, cells were then crosslinked with 2 mM ethylene glycol-bis-succinic acid 
N-hydroxyssuccinimide ester (Santa Cruz Biotechnology) at room temperature for 1 h. Then, the cells were washed 
twice with 1x PBS, resuspended in lysis buffer (5 mM Hepes, pH 8.0; 85 mM KCl; Triton X-100 and proteinase inhib-
itors) and homogenized with a Dounce homogenizer 10 times using a loose pestle. The cell extract was collected by 
centrifugation at 5,400 × g for 1 min at 4 °C, resuspended in nuclei buffer (50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 
1% SDS and protease inhibitors) and incubated for 10 min on ice. IP dilution buffer (20 mM Tris-HCl, pH 8.0; 2 mM 
EDTA; 50 mM NaCl; 1% Triton X-100; 0.1% SDS and protease inhibitors) was added and chromatin was sheared at 
high power for 4 pulses of 5 min in a Bioruptor water bath sonicator (Diagenode Inc., Denville, NJ, USA) to obtain 
fragments of 400 bp or smaller, and centrifuged twice at 16,000 × g for 10 min at 4 °C. Supernatant was collected and 
pre-cleared by incubating with 2 μ g of IgG and 20 uL of protein A (Merck) for 2 h at 4 °C with rotation. The superna-
tant was immunoprecipitated with specific antibodies for 12–16 h at 4 °C. Immunocomplexes were recovered with 
the addition of 20 μ L of protein A or G (for rabbit or mouse IgG, respectively) agarose beads and 1 h incubation with 
rotation at 4 °C. Immunoprecipitated complexes were washed once with sonication buffer (50 mM Hepes, pH 7.9; 
140 mM NaCl; 1 mM EDTA, pH 8.0; 1% Triton X-100; 0.1% sodium deoxycholate; 1% SDS), twice with LiCl buffer 
(100 mM Tris-HCl pH 8.0; 500 mM LiCl; 1% Nonidet P40; 0.1% sodium deoxycholate) and once with TE buffer 
(50 mM Tris–HCl, pH 8.0; 2 mM EDTA). In case of reChIP, the Flag-HBx protein-DNA complexes were eluted by 
incubating with 0.2 mg/mL of 3xFlag-peptide (Sigma) followed by incubation with specific antibodies for 12–16 h 
at 4 °C, continuing the procedure as described. The protein-DNA complexes were eluted with elution buffer (50 mM 
NaHCO3; 1% SDS). NaCl was added to a final concentration of 200 mM. To reverse the crosslinking, immunopre-
cipitated complexes were incubated 12–16 h at 65 °C in the presence of 10 ug of RNase A (Invitrogen). Proteins were 
digested with 25 μ g of proteinase K for 2 h at 50 °C. DNA was recovered with the Zymo Research Kit for DNA Clean 
& Concentrator and analyzed by real-time PCR (KAPA SYBR FAST, Universal qPCR kit). Data were processed as 
follows: from the Ct value obtained with the qPCR, we quantified viral DNA immunoprecipitated with respect to a 
standard curve prepared with the HBV genome. We then eliminated the background value obtained with the IgG 
control. We normalized the values with GAPDH as a loading control and with cccDNA. In the case of analyzing 
histone modifications, we normalized the data against the immunoprecipitated H3.
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Immunofluorescence. 24 h after HBV transfection Huh-7 cells were fixed with 2% paraformaldehyde for 
20 min and washed three times with 1x PBS. Cells were permeabilized with 0.5% Triton X-100 for 5 min, washed 
twice with 1x PBS and unspecific binding sites were blocked with 3% BSA. Cells were incubated overnight at 4 °C 
with antibody against hepatitis B virus core antigen (HBcAg), then rinsed three times with 1x PBS and incubated 
for 1 h with secondary antibody conjugated with Alexa 488 (Rockland). The cells were incubated with DAPI for 
5 min and washed with PBS. Samples were imaged in an Olympus BX51 microscope and HBcAg immunofluores-
cence was quantified with Image J software.
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